Towards optimal management of CV risk: What are the opportunities?

3' education - Oct. 25, 2011

Towards optimal management of CV risk: What are the opportunities?

Prof. MacDonald, University of Dundee, United Kingdom, discusses the challenges in optimizing CV risk. In this expert commentary, the following questions are adressed.

What non-pharmacological measures can be taken in CV risk management?
What pharmacological measures can be taken CV risk management?
What are the new NICE recommendations for the management of hypertension?

Click here to open the webcast in a new window

About the speaker

Professor Tom MacDonald
Hypertension Research Centre & Medicines Monitoring Unit
University of Dundee, United Kingdom

Tom MacDonald is Professor of Clinical Pharmacology and Pharmacoepidemiology in the Department of Medicine and Therapeutics, University of Dundee, and Honorary Consultant Physician at Ninewells Hospital and Medical School. His research interests are hypertension and drug safety. He is a Past President of the International Society of Pharmacoepidemiology, a past member of the pharmacovigilance committee of the committee on safety of medicine and the current Director of the Tayside Medicines Monitoring Unit. He is a past member of the British Hypertension Society Executive. He is the Director of the Regional Cardiovascular Risk Clinic and Hypertension Research Centre at Ninewells Hospital and Medical School. Professor MacDonald has published extensively on drug safety especially the safety of non steroidal anti-inflammatory drugs (NSAIDs). He has also published many studies of patients with cardiovascular risk factors and cardiovascular disorders.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.